197 related articles for article (PubMed ID: 27466480)
1. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.
Karagiannis AK; Girio-Fragkoulakis C; Nakouti T
Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma.
Trimboli P; Lauretta R; Barnabei A; Valabrega S; Romanelli F; Giovanella L; Appetecchia M
Int J Biol Markers; 2018 May; 33(2):156-160. PubMed ID: 29707993
[TBL] [Abstract][Full Text] [Related]
3. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
Lim SK; Guéchot J; Vaubourdolle M
Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
[TBL] [Abstract][Full Text] [Related]
4. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P; Giovanella L
Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of calcitonin and procalcitonin Elecsys
Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L
Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633
[TBL] [Abstract][Full Text] [Related]
6. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
8. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules.
Giovanella L; Imperiali M; Piccardo A; Taborelli M; Verburg FA; Daurizio F; Trimboli P
Eur J Clin Invest; 2018 Jun; 48(6):e12934. PubMed ID: 29635700
[TBL] [Abstract][Full Text] [Related]
9. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.
Trimboli P; Seregni E; Treglia G; Alevizaki M; Giovanella L
Endocr Relat Cancer; 2015 Jun; 22(3):R157-64. PubMed ID: 25934688
[TBL] [Abstract][Full Text] [Related]
10. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
11. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.
Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK
J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.
Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L
Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma.
Kratzsch J; Willenberg A; Frank-Raue K; Kempin U; Rocktäschel J; Raue F
Clin Chem Lab Med; 2021 Oct; 59(11):1861-1868. PubMed ID: 34256421
[TBL] [Abstract][Full Text] [Related]
14. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
17. Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.
Censi S; Di Stefano M; Repaci A; Benvenuti T; Manso J; Pagotto U; Iacobone M; Barollo S; Bertazza L; Galuppini F; Benna C; Pennelli G; Plebani M; Faggian D; Colombo C; Fugazzola L; Mian C
Front Endocrinol (Lausanne); 2021; 12():754565. PubMed ID: 34721303
[TBL] [Abstract][Full Text] [Related]
18. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules.
Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L
Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma.
Bolko P; Manuszewska-Jopek E; Michałek K; Waśko R; Jaskuła M; Sowiński J
Arch Immunol Ther Exp (Warsz); 2003; 51(6):415-9. PubMed ID: 14692663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
